Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Gilenya for MS in Children ≥10 Years

FDA Web site; 2018 May 11

The US Food and Drug Administration (FDA) recently approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents aged ≥10 years. This is the first FDA approval of a drug to treat MS in pediatric patients. Gilenya was first approved by the FDA in 2010 to treat adults with relapsing MS. The FDA granted the approval of Gilenya to Novartis, which is headquartered in Basel, Switzerland.

Most people with MS experience their first symptoms, such as vision problems or muscle weakness, between the ages of 20 to 40. 2-5% of people with MS have symptom onset <18 years and estimates suggest that 8,000 to 10,000 children and adolescents in the US have MS.

Indications: Gilenya is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS) in patients ≥10 years.

Dosage/administration: Recommended dosage for adults and pediatric patients (≥10 years) weighing >40 kg: 0.5 mg orally once-daily, with or without food. Recommended dosage for pediatric patients (≥10 years) weighing ≤40 kg: 0.25 mg orally once-daily, with or without food. Additional information: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/gilenya.pdf.

Adverse reactions: Most common adverse reactions (incidence ≥10% and >placebo): headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.

Citation:

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients. FDA Web site. May 11, 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607501.htm?utm_campaign=05112018_FDA%20approves%20Galenya&utm_medium=email&utm_source=Eloqua. Accessed May 18, 2018.

This Week's Must Reads

Report Card Release, Link to Child Abuse Examined, JAMA Pediatrics; ePub 2018 Dec 17; Bright, et al

Serial Newborn Screening for Hypothyroidism, J Pediatr; ePub 2018 Dec 20; Kaluarachchi, et al

Pediatric Telephone Advice and Language Barriers , Clin Pediatr; ePub 2018 Dec 5; Watts, Hajjar, et al

Antipsychotic Treatment Risk in Children and Youths , JAMA Psychiatry; ePub 2018 Dec 12; Ray, Stein, et al

NAFLD Prevalent in Children with Obesity, J Pediatr; ePub 2018 Dec 14; Yu, et al

Must Reads in Neurology

Surgery/Anesthesia: Effects on Child Development, JAMA Pediatrics; ePub 2018 Nov 5; O’Leary, et al

FDA Approves Xyrem for Pediatric Narcolepsy, Pharmacy Times news release; 2018 Oct 28

Quality of Life Post-Concussion Examined, Clin Pediatr; ePub 2018 Oct 12; Howell, et al

Residential Lead Interventions’ Effect on Children, JAMA Pediatrics; ePub 2018 Aug 27; Braun, et al

Socioeconomic Factors in Childhood Stroke Outcome, Neurology; ePub 2018 Jul 6; Jordan, Hills, et al